Direct Ras G12C Inhibitors: Crossing the Rubicon

Colin Lindsay; Fiona Blackhall

doi:10.1038/s41416-019-0499-1

Direct Ras G12C Inhibitors: Crossing the Rubicon

Colin Lindsay, Fiona Blackhall

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

Despite its status as the most commonly mutated oncogene in cancer, Ras has long been considered ‘undruggable’. In 2019 we will see the first clinical results for direct mutant Ras inhibitors, a result of persistent cross-disciplinary research that has been informed by a number of previous clinical and biological failures.

Original language	English
Journal	British Journal of Cancer.
Early online date	26 Jun 2019
DOIs	https://doi.org/10.1038/s41416-019-0499-1
Publication status	Published - 2019

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41416-019-0499-1Licence: CC BY

Cite this

@article{cb884e13e4e34c6e83c282e648381634,

title = "Direct Ras G12C Inhibitors: Crossing the Rubicon",

abstract = "Despite its status as the most commonly mutated oncogene in cancer, Ras has long been considered {\textquoteleft}undruggable{\textquoteright}. In 2019 we will see the first clinical results for direct mutant Ras inhibitors, a result of persistent cross-disciplinary research that has been informed by a number of previous clinical and biological failures. ",

author = "Colin Lindsay and Fiona Blackhall",

year = "2019",

doi = "10.1038/s41416-019-0499-1",

language = "English",

journal = "British Journal of Cancer.",

issn = "0007-0920",

publisher = "Springer Nature",

}

TY - JOUR

T1 - Direct Ras G12C Inhibitors: Crossing the Rubicon

AU - Lindsay, Colin

AU - Blackhall, Fiona

PY - 2019

Y1 - 2019

N2 - Despite its status as the most commonly mutated oncogene in cancer, Ras has long been considered ‘undruggable’. In 2019 we will see the first clinical results for direct mutant Ras inhibitors, a result of persistent cross-disciplinary research that has been informed by a number of previous clinical and biological failures.

AB - Despite its status as the most commonly mutated oncogene in cancer, Ras has long been considered ‘undruggable’. In 2019 we will see the first clinical results for direct mutant Ras inhibitors, a result of persistent cross-disciplinary research that has been informed by a number of previous clinical and biological failures.

UR - https://www.scopus.com/pages/publications/85068211424

U2 - 10.1038/s41416-019-0499-1

DO - 10.1038/s41416-019-0499-1

M3 - Article

SN - 0007-0920

JO - British Journal of Cancer.

JF - British Journal of Cancer.

ER -

Direct Ras G12C Inhibitors: Crossing the Rubicon

Abstract

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this